Lupin is expecting single digit sales growth in current financial year with sluggish US business likely to impact overall global business of the company. However, the company is anticipating double digit growth in Latin America, South Africa and India. Latin America may grow around mid-to-late 20s in percentage terms, South Africa around 20% and India around 15%.
For the first time in a decade, the company had reported a negative growth in FY18, with net sales dropping to Rs 15,560 crore, a decline of 9% from FY17.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
